A Hamilton patient is the first trial participant to receive a novel experimental immunotherapy for lung cancer.
By: Rosalyn Juergens | August 12, 2014 | Blog
Last week a new imaging probe was administered for the first time to a cancer patient in Hamilton at the HHS Juravinski Hospital and Cancer Centre (JHCC). The research was as the result of many months of collaboration between Dr. Roz Juergens who is a medical oncologists at the JCC, an Assistant Professor in the McMaster Department of Oncology, and an OICR Clinician Scientist; Dr Karen Gulenchyn who is Chief of Nuclear Medicine at HHS and St Joseph’s Hospital and an Associate Professor of Radiology; and Dr. John Valliant who is Director of the Centre for Probe Development and Commercialization (CPDC) at McMaster University and a Professor of Chemistry at McMaster.
The probe called CPD-1028 was made by Dr. Valliant’s team at the CPDC and is designed to image a protein (IGF-1R) expressed on cancers that are often resistant to treatment. The current study is to show that administration of this agent is safe and that it binds to resistant tumors. Then the next phase of the research will be to develop a novel therapeutic agent against IGF-1R.
The first in human study is unique and represents a multidisciplinary collaboration between scientists at McMaster University, HHS, and the Escarpment Cancer Research Institute. The research is supported by the OICR.